Case Study: Using Real World Data to Estimate the Annual Incidence of a Rare Disease
This case study explores how a small pharmaceutical company utilized real-world evidence (RWE) to calculate the national incidence of a rare disease.
Frailty, Real-World Data, and the Access Imperative: A Q&A with Magnolia’s Mike Murphy
At Magnolia Market Access, we see frailty as a key variable in evidence generation and access strategy. Ahead of ISPOR 2025, we sat down with Mike Murphy to discuss Magnolia’s latest research using administrative claims data to evaluate frailty indices.
Prescription Drug Affordability Boards: Considerations to Ensure Patient Access
The issue brief explores the PORTAL toolkit for Prescription Drug Affordability Boards (PDABs), highlighting key concerns and potential impacts on drug pricing, patient access, and policy implementation.
Using EMR Data to Support Budget Impact Modeling
A large pharmaceutical company needed to
demonstrate the potential cost savings of placing a new drug on payer formularies.
Calculating Adherence in the Presence of Variable Follow-Up
A small-size pharmaceutical company was interested in using real-world evidence to compare adherence between two formulations of an oral oncology treatment for Multiple Myeloma (MM).
Using Real-world Data to Support Product Label Change
A mid-size pharmaceutical
company was interested in
obtaining real-world evidence
demonstrating the safety and
effectiveness of higher dosage
chemotherapy for a labeled
oncology indication.
Linking EMR With SDOH Data: Insights Across Disease Cohorts Presentation
AMCP Spring 2024 Platinum Poster and Presentation.
Linking EMR With SDOH Data: Insights Across Disease Cohorts
AMCP Spring 2024 Platinum Poster.
Learnings from Linking Closed Claims Patient Cohorts with Consumer SDOH Data
ISPOR Spring 2024.